Alone or in combination for palliative treatment of malignant tumours, particularly of breast, colon or rectum. Gastric, primary hepatic, pancreatic, uterine (cervical), ovarian & bladder carcinomas.
IV infusion 15 mg/kg in 300-500 mL of 5% glucose over 4 hr, may be continued daily until 1st GI side effects occur. Discontinue treatment until side effects recede then place on maintenance therapy. IV inj 12 mg/kg daily for 3 consecutive days, followed by 6 mg/kg on 5th, 7th & 9th day. Then place on maintenance therapy: 5-10 mg/kg IV inj once wkly.
Hypersensitivity. Bone marrow depression following RT or other antineoplastic agents (leucocyte <5,000/mm3 & platelet <100,000/mm3), suffering from potentially serious infection, known complete dihydropyrimidine dehydrogenase deficiency, poor nutritional state, debilitated. Not to be taken w/in 4 wk of brivudine, sorivudine or chemically-related analogues. Pregnancy.
Not to be re-administered after documented CV reaction (arrhythmia, angina, ST segment changes). Discontinue use if leucopenia, thrombocytopenia, stomatitis, oesopharyngitis, intractable vomiting, diarrhoea, melena, haemorrhage, oral ulceration, GI ulceration or bleeding, multifocal inflammatory leucoencephalopathy occurs. Myelosuppression; cardiotoxicity, history of heart disease; bone marrow depression, high-dose pelvic irradiation, previous treatment w/ alkylating agents; palmar-plantar erythrodysesthesia syndrome. Monitor platelets & WBC counts daily. Dihydropyrimidine dehydrogenase deficiency. Avoid prolonged exposure to sunlight. Interference w/ diagnostic thyroid function tests. Avoid use w/ live or live-attenuated vaccine. Concomitant use w/ phenytoin, other chemotherapeutic agents, folinic acid. Renal & hepatic impairment; jaundice. Women of childbearing potential & male partners should use adequate contraception. Not to be used during pregnancy & lactation. Elderly ≥70 yr.
Sign Out
